Regeneron Pharmaceuticals, Inc. which can be found using ticker (REGN) have now 24 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $1,229.00 and $720.00 calculating the mean target share price we have $1,071.89. (at the time of writing). Given that the stocks previous close was at $1,071.12 this would imply there is now a potential upside of .1%. The 50 day moving average now sits at $1,004.53 and the 200 day MA is $917.66. The market capitalization for the company is 119.03B. The stock price for the company is currently $1,080.27 USD
The potential market cap would be $119,116,196,340 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 31.91, revenue per share of $122.57 and a 7.74% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
